PLEASONTON, CALIF., NANJING, and SHANGHAI, August 12, 2021 - IASO Biotherapeutics (IASO Bio) announced that the preclinical results of the company’s proprietary next-generation chimeric antigen ...
PLEASONTON, CALIF., NANJING, and SHANGHAI, July 29, 2021 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, tod...
PLEASANTON, CALIF., NANJING, CHINA, June 15, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies f...
Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a les...
PLEASANTON, CALIF., NANJING, CHINA, June 8, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies fo...
PLEASANTON, CALIF., NANJING, CHINA, June 3, 2021-—IASO Biotherapeutics (IASO Bio), and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the results of initial clinical s...